Edition:
United States

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

2.24USD
14 Aug 2018
Change (% chg)

$-0.05 (-2.18%)
Prev Close
$2.29
Open
$2.22
Day's High
$2.28
Day's Low
$2.19
Volume
33,633
Avg. Vol
35,383
52-wk High
$7.68
52-wk Low
$1.84

Latest Key Developments (Source: Significant Developments)

Sunesis Pharmaceuticals Qtrly Loss Per Share $0.21
Tuesday, 8 May 2018 04:00pm EDT 

May 8 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 REVENUE $200,000 VERSUS I/B/E/S VIEW $200,000.QTRLY LOSS PER SHARE $0.21.  Full Article

Sunesis Pharma Qtrly Loss Per Share $0.21
Thursday, 8 Mar 2018 04:05pm EST 

March 8 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.QTRLY LOSS PER SHARE $0.21.Q4 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.  Full Article

Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017
Monday, 4 Dec 2017 04:05pm EST 

Dec 4 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017.SUNESIS PHARMACEUTICALS INC - SWISHER TO REMAIN WITH SUNESIS AS A STRATEGIC ADVISOR.SUNESIS PHARMACEUTICALS INC - BOARD MEMBER DAYTON MISFELDT APPOINTED INTERIM CEO EFFECTIVE JANUARY 2018.  Full Article

Sunesis Pharmaceuticals Appoints William Quinn As CFO
Thursday, 30 Nov 2017 07:00am EST 

Nov 30 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT.SUNESIS PHARMACEUTICALS INC - ‍WILLIAM QUINN MOST RECENTLY SERVING AS CEO AND CO-FOUNDER OF PRIVATE CANCER IMMUNOTHERAPY COMPANY BULLET BIOTECHNOLOGY​.  Full Article

Sunesis Pharmaceuticals Inc Q3 loss per share ‍$0.43​
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals reports third quarter 2017 financial results and recent highlights.Sunesis Pharmaceuticals Inc qtrly loss per share ‍$0.43​.Sunesis Pharmaceuticals Inc- ‍pro-forma Sept 30, 2017 cash, cash equivalents and marketable securities of $37.1 million is expected to fund co into 2019​.  Full Article

Sunesis announces pricing of $20 million offering of securities
Wednesday, 25 Oct 2017 08:54am EDT 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc ::Sunesis announces pricing of $20 million offering of securities.Sunesis Pharmaceuticals Inc - pricing of underwritten public offerings of 7.5 million shares and accompanying warrants to purchase 3.8 million shares​.Sunesis Pharmaceuticals- ‍also priced 2,500 shares of non-voting series D convertible preferred stock, accompanying warrants to purchase 1.3 million shares​.  Full Article

Sunesis Pharmaceuticals announces proposed public offering of common stock, preferred stock and warrants
Tuesday, 24 Oct 2017 04:05pm EDT 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis announces proposed public offering of common stock, preferred stock and warrants.Sunesis Pharmaceuticals Inc - ‍anticipates using net proceeds from proposed offerings to fund development of sns-062, additional kinase inhibitor programs​.  Full Article

Sunesis Pharmaceuticals reports second quarter results
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals reports second quarter 2017 financial results and recent highlights.Says loss from operations for three months ended June 30, 2017 was $8.6 million.Says as of June 30, 2017, cash, cash equivalents and marketable securities totaled $22.7 million..  Full Article

Balyasny Asset Management reports 9.32 pct passive stake in Sunesis Pharmaceuticals
Wednesday, 5 Jul 2017 02:29pm EDT 

July 5 (Reuters) - Balyasny Asset Management::Balyasny Asset Management reports a 9.32 percent passive stake in Sunesis Pharmaceuticals Inc as of June 23, 2017 - SEC filing.  Full Article

Sunesis Pharmaceuticals amends loan agreement
Friday, 30 Jun 2017 05:05pm EDT 

June 30 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals Inc - on June 30, 2017, co entered into an amendment, or amendment, to loan and security agreement dated march 31, 2016.Sunesis Pharmaceuticals Inc - amendment modifies loan repayment terms to be interest-only through july 1, 2018.  Full Article

BRIEF-Sunesis Pharmaceuticals Qtrly Loss Per Share $0.21

* SUNESIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS